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Summary One hundred and one consecutive patients with newly diagnosed stage I Hodgkin's disease (HD)
received treatment at St Bartholomew's Hospital, between 1968 and 1987, with a median follow-up of 12
years. Eleven patients have been excluded from detailed analysis because they either received involved field
radiotherapy (RT) or radiotherapy with chemotherapy or were lost to follow-up. Actuarial analysis predicts
78% to be alive and without relapse of Hodgkin's disease at 15 years. Ninety evaluable patients (clinical stage
(CS) 24; pathological stage (PS) 66) received either mantle or inverted 'Y' RT and form the basis of this
analysis. The median age was 33 years (63 men, 27 women). Histology at presentation was nodular sclerosing
(39), lymphocytic predominant (27) or mixed cellularity (24). The presenting site was neck (78), axilla (6) groin
(4) and mediastinum (2). Complete remission was achieved in all evaluable patients, the actuarial proportion in
remission being 75% at 15 years. Factors predictive of a prolonged remission were pathological staging versus
clinical staging (P = 0.02) and lymph node size <3 cm (P = 0.04). Actuarial overall survival in these 90
patients was 75% at 15 years and none of the above factors correlated with survival. Relapse of HD has
occurred in 18 patients (5 within RT field, 10 without and 3 in both). Second remission was achieved in 15/18.
The actuarial rate of second remission and survival was 40% at 10 years. Sixteen patients have died, 7 of
Hodgkin's disease, 7 of unrelated causes and 2 of second malignancy. A further 3 patients who developed
second malignancy are still alive. At 15 years the actuarial mortality related to HD was 12%. These results
confirm the importance of long follow up to assess the efficacy of primary therapy.
Finzi suggested, from St Bartholomew's Hospital, in 1913
that extending the irradiation field beyond that required to
encompass the involved nodes to include contiguous areas
might improve the prognosis of localised Hodgkin's disease
(HD). This view was supported by Gilbert (1939), Craft
(1940), Peters (1950, 1958), Easson (1963), and particularly
reinforced by Kaplan (1962), such that extended field
megavoltage radiotherapy, has become the accepted treat-
ment of choice, for patients with localised HD to this present
day. The techniques available for determining the extent of
HD have improved considerably during the past thirty years,
with lymphangiography and latterly computerised axial
tomography (CAT) for delineating intra-abdominal lymph
nodes, and laparotomy in selected instances for detecting
splenic and hepatic involvement. This has inevitably led to
greater precision of staging, and hence, possibly to an appar-
ent improvement in the results of radiotherapy for localised
HD.
The results presented below demonstrate what may be
achieved with a uniform policy of mantle radiotherapy for
supradiaphragmatic and inverted 'Y' for infradiaphragmatic
stage I HD. All cases were documented with lymphangio-
graphy or CAT scanning, and in the majority with staging
laparotomy. This report extends upon the previously pub-
lished observations (Timothy et al., 1978).
Materials and methods
Patients
One hundred and one of 607 consecutive previously un-
treated adults with HD referred to the Departments of
Medical Oncology and Radiotherapy at St. Bartholomew's
Hospital between 1968 and 1987 were demonstrated by the
techniques described below to have stage I HD. The histo-
logical diagnosis in all instances was made by one of us
(A.G.S.) and has been subsequently reviewed (J.D.), being
classified according to the Rye nomenclature (Lukes et al.,
1966).
There were 72 men and 29 women, the median age being
33 years (range 13-72). Only 5 patients presented with infra-
diaphragmatic disease (all were stage IA). Four patients
presented with 'B' symptoms. Eleven patients are analysed
separately, 10 because they received either involved field
radiotherapy (IF), mantle irradiation and chemotherapy or
chemotherapy alone essentially for clinical reasons, and one
because he was lost to follow-up treatment (Table I).
Detailed analysis has been performed on 90 evaluable
patients who received extended field irradiation as primary
treatment (Table II).
Investigation
Between 1968 and 1972, clinical examination, complemented
by plain chest radiography with hilar tomography and bi-
pedal lymphangiography, biochemical tests of liver function
and bone marrow biopsy were employed to determine clinical
stage (CS) for eighteen patients. In 1972, pre-treatment
laparotomy with multiple lymph node biopsies, liver biopsy
and splenectomy was introduced to provide a full patho-
logical stage (PS). Pathological staging of 93 patients with CS
Table I Details of patients excluded from analysis (11 patients)
No. of
Stage Therapy Reason patients
I CS IA IF Clinical 3
2a PS IA TNI Clinical 1
3b PS IA EF + MVPP Clinical 2
4 PS IA INV 'Y' + MVPP Clinical 1
5 CS IA MVPP Error 1
6 PS IA IF + MOPP Diagnostic I
problem
7c CS IA CHLVPP + EF Clinical 1
8 CS IB MANTLE Lost to I
follow-up
aPatient who had a relapse of HD. bOne patient who died in
remission of HD due to carcinoma of the bronchus; cinfection
associated with diabetes mellitus. IF=involved field irradiation;
EF = extended field irradiation; TNI = total nodal irradiation.
Correspondence: T.A. Lister.
Received 26 October 1989; and in revised form 21 February 1990.
Br. J. Cancer (1990), 62, 314-318 19" Macmillan Press Ltd., 1990RADIOTHERAPY FOR STAGE I HD 315
Table II Clinical details of patients receiving mantle or inverted 'Y'
irradiation (90 patients)
Total CS PS
IA 87 21 66
IB 3 3
Age (median) 33 32 31
Sex (M/F) 63/27 17/7 46/20
Site
Neck 78 22 56
Axilla 6 2 4
Inguinal 4 4
Thymus 2 2
Histology
Nodular sclerosing 39 12 27
Lymphocyte 27 5 22
predominant
Mixed cellularity 24 7 17
second remission after relapse was estimated from the date of
re-evaluation after completion of therapy. Statistical
significance was determined using the log rank method (Peto
et al., 1977).
Results
Overall
Complete remission was achieved in all 101 patients (Figure
1). Eighty-two are still alive with a median follow up of 12
years (Figure 2). Nineteen are dead, 6 from recurrent HD, 3
from second malignancy, 2 from infection and 8 from
unrelated causes. The overall results were the same for those
treated with mantle or inverted 'Y' radiotherapy as for those
with protocol violations, but the results of the former group
have been analysed separately in detail to give information
about that specific therapy.
stage 1 between 1972 and 1987 confirmed stage I in 71
patients but 22 became PS IIIA. The mean delay in com-
mencing therapy due to pre-treatment laparotomy was 7
weeks. Twelve additional patients with CS stage I HD did
not proceed to laparotomy, because of special circumstances
and were treated on basis of clinical stage.
Treatment
Radiation treatment over the period of study was given by
extended field irradiation (mantle or inverted 'Y') by linear
accelerators of beam energy 4-20 Mev using parallel
opposed fields. Treating both fields daily, a midline dose of
35 Gy in 20 fractions over 28 days was prescribed followed
by a further 5 Gy in three fractions to the site of original
disease. Lung shielding was initially by a variety of standard-
ised lead blocks, but after 1974 all patients had individually
moulded cerrobend alloy lung blocks. The cervical spine was
shielded from the posterior field after a mid-line dose of
20 Gy. Tissue equivalent bolus was applied in the cervical
and axillary regions to reduce dose inhomogeneity, even
though this resulted in loss of skin sparing and a moderate
skin reaction in some patients. The lower border of treatment
volume for mantle irradiation was at the lower border of the
tenth thoracic vertebra. The spleen or splenic pedicle were
not included in the treatment volume during mantle or
inverted 'Y' irradiation. Patients with recurrent disease
received cyclical combination therapy comprising mustine,
vinblastine, prednisolone and procarbazine (MVPP) (Nichol-
son et al., 1970) or variants in the first instance, and palli-
ative care with single agents or radiotherapy if subsequently
appropriate.
Follow-up was at least every 3 months for the first year,
every 6 months up until 5 years and annually thereafter. This
comprised clinical examination, chest X-ray, full blood count,
sedimentation rate (esr) and biochemical tests of liver func-
tion. Plain X-rays of the abdomen were repeated until no
further contrast was visible, but refill lymphangiograms were
not performed without clinical indication. Thyroid function
was assessed regularly and thyroxine prescribed for
biochemical evidence of hypothyroidism regardless of the
clinical situation. Penicillin was prescribed up to the age of
25 years for all patients who had undergone splenectomy,
and Pneumovax vaccine has been recommended since it
became available.
Statistical analysis
Overall survival was calculated from the date of diagnosis
until death and disease-free survival figures were taken from
the date of complete remission to relapse. Patients who died
in remission were censored from the duration of remission
curves and all deaths except those due to HD were excluded
in the cause-specific curves. Statistical analysis was by the life
table method of Kaplan and Meier (1958). Duration of
Patients receiving mantle or inverted 'Y' (90 patients)
Duration ofremission Seventy-two of the 90 patients remain
in remission, 18 having relapsed between 1 and 11 years
(Figure 3). By univariate analysis the duration of remission
was significantly longer for surgically staged patients as
opposed to clinically staged patients (Figure 4, P = 0.02).
The pattern of relapse was different between CS and PS
patients (Table III) with more relapses occurring outside the
radiation field in the former group, though it was not statisti-
cally significant (P = 0.08). Overall, lymphadenopathy
recorded as greater than 3 cm correlated adversely with dura-
tion of remission (Figure 5, P = 0.04). In patients who were
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Figure 1 Actuarial duration of first remission for 101 patients
with stage I Hodgkin's disease.
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Figure 2 Actuarial overall survival for 101 patients with stage I
Hodgkin's disease (19 deaths).
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Figure 3 Actuarial duration of first remission for 90 evaluable
patients with stage I Hodgkin's disease.
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Figure 5 Size of lymphadenopathy at presentation correlated
with actuarial duration of first remission.
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Figure 4 Actuarial duration of first remission in clinically (CS)
and pathologically staged (PS) patients.
Table III Details of patients who had recurrence of HD (18
patients)
Sites of relapse
Within Outside
RTfield RTfield' Both Response Outcome
CS
(9/24) 2 5 2 7 CR 4 alive in CR
2 PR 5 died of HD
PS
(9/66) 3 5 1 8 CR 5 alive in CR
I died of HD
3 other causes
CR denotes complete remission; PR denotes partial remission. RT
denotes radiotherapy. 'All relapses were trans-diaphragmatic.
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Figure 6 Actuarial duration of remission correlated with size of
lymphadenopathy and staging.
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Figure 7 Actuarial duration of second remission following
relapse in 15 patients.
staged clinically, size of lymph nodes correlated strongly with
duration of remission (P = 0.008), but the trend was not
significant for PS patients. The two significant factors
identified at univariate analysis were interdependent as shown
in Figure 6. The combination of clinical stage and large
lymph nodes predicted a distinctly inferior outcome com-
pared to the other three groups (P = 0.00002). Age, sex
histology and erythrocyte sedimentation rate did not cor-
relate with duration of remission.
Seventeen of the 18 patients in whom relapse occurred
were treated with combination chemotherapy, complete
remission being achieved in 14/17 patients. One died of septi-
caemia during therapy, and there was progressive disease
despite therapy in the remaining 2 patients. The remaining
patient received inverted 'Y' therapy to achieve complete
remission. Nine of the 15 patients remain in remission, 6
having relapsed between 1 and 7 years (Table III, Figure 7).
There was no correlation between the dose of radiation with
site or frequency of relapse.
Survival from presentation Seventy-four of the 90 patients
are still alive, the remainder having died between 3 and 18
years (Figure 8). None of the prognostic factors analysed for
duration of remission correlated with survival. Sixteen
patients have died, 6 of progressive HD after relapse, one of
septicaemia following therapy for relapse, 2 of second malig-
nancy (Non-Hodgkin's lymphoma, carcinoma of the bron-
chus) and 7 of unrelated causes. The predicted cause-specific
survival was 90% at 15 years (Figure 9).
Survivalfrom relapse Eight of the 18 patients who relapsed
are alive, the remaining 10 having died within 5 years (Figure
10).
Second malignancy and 'complications' Five patients have
developed a second malignancy at least 1 year from com-
pletion of therapy. It has been fatal, to date, in two (Table
IV). There was no post splenectomy septicaemia in this group
of patients. No major complications of radiotherapy were
observed.
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One of the 11 patients has relapsed and is in second remis-
sion. Two have died, 1 of carcinoma of the bronchus and the
other due to infection and diabetes mellitus (Table I).
Discussion
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relapse of Hodgkin's disease.
The analysis of the results of therapy of 101 adults demon-
strates that the short term prognosis of stage I HD treated
with mantle or inverted 'Y' is excellent but that there is an
appreciable related mortality in the group of people up to 20
1'2 1'62,4 years, either disease related, or not. Although overall survival
(Ye )6 20 24 was the same for those undergoing laparotomy as for those
(Years) treated on the basis of clinical stage, the pattern of life for
val of 90 patients with stage I these two groups was different, since the latter had a much
higher requirement for multiple therapy.
The significance of the five instances of second malignancy
is as yet unclear, particularly since half of them were com-
mon and might have occurred by chance. Longer follow-up,
N = 90 and extrapolation from other series will be required to deter-
mine whether there will be more and different, second
cancers in patients receiving multiple therapy as opposed to
radiotherapy alone (Kaldor et al., 1990; Henry-Amar, 1983).
The results are comparable with the published literature, if
it is assumed that this patient population corresponds with
that of the most favourable localised Hodgkin's disease
reported by others (Hoppe et al., 1982; Cornbleet et al., 1985;
Fuller et al., 1980; Tubiana et al., 1985; Mauch et al., 1988;
Hagemeister et al., 1982). The great majority of patients were
without constitutional symptoms, younger and did not have
residual disease following therapy. The treatment prescribed
1i6 20 24 was almost entirely (90/101) 'limited' extended field mega-
e (Years) voltage radiotherapy and as such was almost without side-
effects. It yielded results highly comparable to those of the
1 survival of 90 patients with European Organisation for Research on Treatment of Cancer
(EORTC) in the randomised trial H5, in which it was shown
that mantle radiotherapy was as effective as mantle and
paraortic irradiation in patients with stage I HD, selected on
the basis of prognostic factors to undergo staging
laparotomy (Carde et al., 1988). It is further corroborated by
the results reported from Boston wherein staging laparotomy
was consistently performed with mantle, paraortic and
splenic irradiation in stage I HD (Mauch et al., 1988).
Although involved field irradiation alone has been reported
to result in the same survival at 10 years, this approach
accepts an increased relapse rate and the necessity of subse-
quent treatment. The poor outcome of the patients who
relapsed in our series call this approach into question (Stoffel
et al., 1977; Rosenberg & Kaplan, 1985; Collaborative Study,
N - 18 1984). The importance of these results to the debate about
18, I _, staging laparotomy is solely in confirming that if it is per-
9 12 15 18 formed and negative, mantle irradiation is associated with as
(Years) low a rate of recurrence as more extensive irradiation.
,vival of 18 patients after first If the laparotomy is not performed, more treatment in the
form of wider field therapy has been reported to be equally
Table IV Details of patients with second neoplasms
Age Year Nature
at Year of 2nd 2nd
diagnosis Stage diagnosis Therapy neoplasm neoplasm
1 58 PS IA 1973 Mantle 1980 Bladder carcinoma
2a 47 PS IA 1972 Mantle 1987 Adenocarcinoma lung
MVPP at
relapse
3 20 CS IA 1968 Mantle 1982 Seminoma testis
4a 35 CS IA 1968 Mantle 1983 Non-Hodgkin's
lymphoma
5 30 CS IA 1969 Mantle 1989 Cancer breast
aDied due to second neoplasm in remission of Hodgkin's disease.
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effective without increase in short term toxicity. For most
centres this has been limited to extending the mantle field
down the paraortic chain. The H6 EORTC trial (Tubiana et
al., 1989) has, however, reintroduced splenic irradiation for
clinically staged patients comparing it with laparotomy and
mantle irradiation for 'favourable' patients, both yielded
similar results at 4 years. Longer follow-up will determine
whether there is a greater morbidity or mortality with the
larger radiation field (Sutcliffe et al., 1985).
The choice of therapy is also determined by the potential
complications of laparotomy, namely, overwhelming sepsis
(Coker et al., 1983), possible contribution towards the
development of secondary leukaemia (Van Leeuwen et al.,
1987), and delay in instituting radiation therapy. More data
are becoming available to provide accurate predictions of the
likely outcome of the operations in relation to presentation
variables (Leibehaut et al., 1989; Tubiana et al., 1989), which
may lessen the dilemma.
The above results confirm the good progress of stage I HD
treated by primary radiotherapy. It is notable, however, that
an appreciable risk of relapse persists up to 9 years after
therapy and therefore prolonged follow up is essential. Fur-
thermore, 1 in 3 of patients who relapsed subsequently died
of HD. While it may be possible to reduce therapy for
selected patients at presentation, thereby also reducing tox-
icity, considerable thought must be given to those who
relapse. Particular attention must be given to defining the
criteria for proceeding to therapy requiring bone-marrow
rescue.
We are delighted to acknowledge the contribution of the medical,
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and Medical Oncology for the care of the patients. Laparotomies
were performed predominantly by Professor M. Irving, Professor I.
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bility of Dr A. Tucker and Dr R. Reznek, and the bone marrows
were examined by Dr J. Amess. The manuscript was typed by Dr
T.S. Ganesan and corrected by Sian Comber. J. White was respons-
ible for collating the data and W. Gregory for statistical analysis.
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